Neurorehabilitation Devices Market

Market Overview

The global neurorehabilitation devices market size was valued at USD 1,084.25 million in 2022. It is estimated to reach USD 3,309.38 million by 2031, growing at a CAGR of 13.2% during the forecast period (2023–2031). The global neurorehabilitation devices market is primarily boosted by the surging prevalence of neurological illnesses like migraine, dementia, Alzheimer's disease, brain tumors, epilepsy, and others worldwide. Moreover, the demand for innovative and effective technologies is expected to increase in tandem with the growing population requiring neurorehabilitation treatments, leading to the introduction of new products in the market and thereby creating opportunities for market expansion.

Neurorehabilitation devices refer to medical equipment specifically developed to assist in the process of rehabilitating and recuperating individuals who have been affected by neurological illnesses or traumas. These devices are employed to enhance or reinstate the operational capabilities of the neurological system, encompassing the brain, spinal cord, and peripheral nerves. Neurological illnesses and traumas can lead to various impairments, including abnormalities in motor function, sensory perception, and cognitive abilities.

Neurorehabilitation devices can address multiple facets of rehabilitation and are frequently utilized with additional therapeutic approaches. The primary objective of neurorehabilitation devices is to optimize overall well-being and promote self-sufficiency among those afflicted with neurological disorders. These gadgets are frequently employed as components of a comprehensive rehabilitation regimen customized to cater to each person's unique requirements.

Market Dynamics

Global Neurorehabilitation Devices Market Drivers

Increasing Prevalence of Neurological Diseases

The surging incidence of neurological disorders such as migraine, dementia, Alzheimer's disease, brain tumours, epilepsy, and others are expected to boost the market growth. For instance, recent World Health Organization (WHO) research shows that neurological illnesses affect approximately one billion individuals. Similarly, according to a 2020 Lancet study, neurological illnesses rank as the second greatest cause of death worldwide, contributing to 9 million deaths annually, and are the main cause of disability-adjusted life years.

Furthermore, according to WHO, epilepsy accounts for around 13 million disability-adjusted life years and is accountable for more than 0.5% of the global disease burden. In addition, increasing cases of Alzheimer's disease in older people are expected to fuel market growth. For instance, according to WHO, globally, approximately 50 million have dementia and about 10 million new cases are reported every year. Such a high prevalence of neurological disorders globally is expected to boost the growth of the global neurorehabilitation devices market.

Growing Geriatric Population

The fall in fertility rates and increased life expectancy have resulted in an aging population. Almost every country in the world is experiencing growth in the geriatric population. As per the United Nations Report, in 2022, the global population aged 65 and overreached 771 million, representing approximately 10% of the global population. Projections indicate that it is anticipated to reach a pace of 16% by the year 2050 and is further forecast to escalate to 24% by the year 2100.

The prevalence of diseases such as Alzheimer's is higher among the geriatric population. Due to the simultaneous growth and aging of populations, coupled with the rising prevalence of significant neurological disorders that are closely associated with advancing age, governments will inevitably encounter a mounting need for the provision of treatment, rehabilitation, and support services for such disorders. Thus, an increase in the global geriatric population is expected to propel the global demand for neurorehabilitation devices.

Global Neurorehabilitation Devices Market Restraint

Lack of Technical Experts

One significant barrier that hinders the market's growth is the limited availability of skilled technical specialists who comprehensively comprehend neurorehabilitation devices' functionalities and control systems. Based on the findings of the McKinsey Global Institute 2020 research, it has been determined that the public sector of the EU-28 is confronted with a deficiency in skills, amounting to approximately 8.6 million individuals. This shortage is distributed across three distinct areas, namely technology skills (1.7 million), digital citizenship skills (3.2 million), and traditional skills (3.2 million), with a cumulative deficit of 3.7 million individuals. Moreover, it is argued that developing economies face considerable challenges in substantially advancing their healthcare systems. Such factors hinder the market's growth.

Global Neurorehabilitation Devices Market Opportunities

Technological Advancements

The key participants in the market are focused on introducing new technologically advanced products to cater to the surging demand for neurorehabilitation devices. For instance, in January 2019, A prominent manufacturer of neurorehabilitation devices, Flint Rehab, officially introduced MiGo, the first wearable activity tracker designed particularly for stroke survivors and made commercially available. MiGo monitors activity in the upper extremities, encompassing locomotion and movement patterns exhibited by individuals diagnosed with stroke. A smartphone application is integrated with the device to offer motivational assistance through digital coaching, progressive goal establishment, and social networking with fellow stroke survivors.

Additionally, in March 2019, BeAble Health, an Indian Institute of Technology Hyderabad-incubated startup, created a Gamified Arm Rehabilitation Device 'ArmAble' to assist in the motor rehabilitation of stroke victims with upper motor deficits and the neuro-rehabilitation of victims. The ArmAble system effectively meets the pressing need for a standardized, engaging, and rigorous approach to upper limb rehabilitation. It targets conditions including frozen shoulder, multiple sclerosis, cerebral palsy, and traumatic brain injury. Such developments are expected to create opportunities for market growth.

Regional Analysis

Based on region, the global neurorehabilitation devices market is bifurcated into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

North America Dominates the Global Market

North America is the most significant global neurorehabilitation devices market shareholder and is expected to expand substantially during the forecast period. The market in North America is expected to grow due to various factors, such as the burden of neurological disorders and an increase in favorable government initiatives. Moreover, increasing product launches, approvals, and demand for neurorehabilitation devices are expected to positively impact the North American neurorehabilitation devices market share. For instance, in April 2021, The U.S. Food and Drug Administration granted marketing authorization for a novel device designed to assist in muscle re-education and to maintain or increase range of motion in stroke rehabilitation patients aged 18 and older. A Brain-Computer-Interface (BCI) device, the Neurolutions IpsiHand Upper Extremity Rehabilitation System (IpsiHand System), aids in rehabilitating stroke patients with hand, wrist, and arm impairments.

In addition, the region's funding for the R&D of novel neurorehabilitation devices is high. For instance, in August 2022, Neurofenix, a health technology firm from the United Kingdom, secured a capital investment amounting to EUR 7 million. This funding will be employed to expand its range of products and initiate clinical trials in the United States. The startup is implementing an innovative and patient-centered strategy for recovery and at-home neurorehabilitation therapy, demonstrating increased engagement and support. All these factors are together contributing to the regional market growth.

In Europe, the high prevalence of neurological disorders, such as stroke, Multiple Sclerosis (MS), Alzheimer's Disease (AD), Motor Neuron Disease (MND), Parkinson's Disease (PD), and Huntington's Disease (HD), is a major concern for healthcare agencies and governments. For instance, according to Alzheimer Europe, the estimated population of individuals living with dementia in the European Union (EU27) is 7,853,705, whereas, in European nations represented by AE members, it is anticipated to be 9,780,678. The prevalence of dementia in Europe is projected to experience an almost twofold increase by the year 2050, with estimates indicating a rise to 14,298,671 individuals affected within the European Union and 18,846,286 individuals affected in the broader European region.

Additionally, the soaring geriatric population in the region is further fostering market development. For instance, Eurostat said more than one-fifth (21.1%) of the EU population was 65 or older in 2022. Furthermore, the predicted increase in the median age of the EU-27 is estimated to be 4.5 years from 2019 to 2050, resulting in a median age of 48.2 years. This is expected to boost the regional market expansion.

The Asia-Pacific region's market is anticipated to rise due to increased clinical trials in developing nations like China and India, a rising disease burden, and a growing demand for treatments that target the central nervous system. Additionally, increasing disposable income, improving healthcare infrastructure, and rising consumer awareness will likely be key market drivers in the Asia-Pacific region. Similarly, establishing new rehabilitation facilities in the region boosts market expansion. For instance, in March 2023, Lupin, a Mumbai pharmaceutical company, inaugurated Atharv Ability, an advanced neuro-rehabilitation facility in the Bandra Kurla Complex (BKC). A comprehensive suite of cutting-edge devices, including a balance training and postural control system, an end-effector-based robotic solution for gait and hand training, occupational therapy, cognitive behavioral therapy, speech therapy and swallowing therapy, aqua therapy, visual therapy, and virtual reality, is available at the neuro-rehabilitation center.

Segmental Analysis

The global neurorehabilitation devices market is segmented by product, application, and end-user.

Based on product, the global market is divided into neurorobotics, brain-computer interface, wearable devices, non-invasive stimulators, and others. 

The neurorobotics segment dominates the global market and is expected to expand substantially over the forecast period. Neurorobotics is a field of study that integrates artificial intelligence (AI), robotics, and neuroscience. Neurorobotics aims to create machines capable of simulating or imitating the operations of the human nervous system. This requires incorporating neuroscience principles and insights into robotic system design and control. The fundamental concept underlying neurorobotics is replicating and comprehending the intricate interplay among the brain, body, and surroundings.

Neurorobotics in neurorehabilitation pertains to the amalgamation of principles from robotics and neurology to fabricate apparatus and systems that aid in rehabilitating individuals afflicted with neurological impairments. These devices are engineered to deliver individualized and focused rehabilitation interventions that adjust to each patient's requirements and capabilities.

Based on application, the global neurorehabilitation devices market is bifurcated into stroke, Parkinson's disease, multiple sclerosis, cerebral palsy, and others. 

The stroke segment is the highest contributor to the market and is expected to expand significantly over the forecast period. The utilization of neurorehabilitation devices is of paramount importance in the context of stroke therapy, as they contribute significantly to the recovery and rehabilitation of individuals who have undergone a stroke. Stroke is a medical illness that frequently leads to neurological impairments, encompassing motor dysfunction, sensory deficiencies, and cognitive difficulties. Neurorehabilitation devices are specifically engineered to enhance rehabilitation and assist patients in recovering impaired functions.

The incorporation of neurorehabilitation devices within stroke therapy endeavors to optimize the capacity for recuperation, amplify patient engagement, and offer rehabilitation programs that are more precise and tailored to individual needs. These technologies are prominent in facilitating a complete and interdisciplinary approach to stroke rehabilitation, enhancing stroke patients' overall results and quality of life.

Based on end-users, the global market is divided into rehabilitation centers, hospitals and clinics, home care, and others. 

The hospitals and clinics segment owns the highest neurorehabilitation devices market share and is expected to expand substantially throughout the forecast period. Hospitals and clinics hold a significant share of the neurorehabilitation devices market, as most rehabilitation is done in hospitals. Moreover, the growing number of hospitals and specialty clinics across developing countries positively impacts the demand for neurorehabilitation devices. For instance, as per the American Hospital Association Annual Survey 2021, in the United States, there were 1,805 rural community hospitals, 3,336 urban community hospitals, and 3,453 community hospitals in a system in 2019.

In addition, total admissions in all United States hospitals were around 36,241,815 in 2019. Effective reimbursement policies offered in hospitals in certain countries around the world, which ease the medical cost burden on the patient, also contribute to the growth of the hospital segment.

Recent Developments

• October 2023- MedRhythms, a company headquartered in the United States, declared its neurorehabilitation system InTandem prescription-only, accessible to individuals afflicted with chronic walking impairments caused by stroke.
• August 2023- ReWalk Robotics Ltd. ("ReWalk"), a prominent supplier of cutting-edge technologies that facilitate mobility and well-being for individuals with neurological disorders during rehabilitation and daily life, announced the completion of a final agreement to acquire AlterG, Inc. ("AlterG"), a pioneering provider of Anti-Gravity systems utilized in physical and neurological rehabilitation.